Epiphany Bio Raises $36 Million

Epiphany Biosciences, a San Francisco-based biotech company focused on discovering and developing anti-infective therapeutics, has raised $36 million in Series A funding. Wexford Capital led the deal, and was joined by Windsor Bay Capital, Global Trust Ventures Management, CDIB BioScience Venture Management and several angels. www.epiphanybio.com< ?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" />